160 related articles for article (PubMed ID: 38235369)
1. Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada.
Jeong D; Wong S; Karim ME; Manges AR; Makuza JD; Bartlett SR; Velásquez García HA; Luster D; Adu PA; Binka M; Yu A; Krajden M; Janjua NZ
Lancet Reg Health Am; 2024 Jan; 29():100658. PubMed ID: 38235369
[TBL] [Abstract][Full Text] [Related]
2. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
Janjua NZ; Wong S; Abdia Y; Jeong D; Buller-Taylor T; Adu PA; Samji H; Wilton J; Pearce M; Butt ZA; Yu A; Binka M; Bartlett S; Alvarez M; Krajden M
J Hepatol; 2021 Nov; 75(5):1049-1057. PubMed ID: 34097994
[TBL] [Abstract][Full Text] [Related]
3. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
[TBL] [Abstract][Full Text] [Related]
4. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.
Janjua NZ; Wong S; Darvishian M; Butt ZA; Yu A; Binka M; Alvarez M; Woods R; Yoshida EM; Ramji A; Feld J; Krajden M
J Viral Hepat; 2020 Aug; 27(8):781-793. PubMed ID: 32187430
[TBL] [Abstract][Full Text] [Related]
5. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
[TBL] [Abstract][Full Text] [Related]
6. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
8. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
10. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals.
Bartlett SR; Yu A; Chapinal N; Rossi C; Butt Z; Wong S; Darvishian M; Gilbert M; Wong J; Binka M; Alvarez M; Tyndall M; Krajden M; Janjua NZ
Liver Int; 2019 Dec; 39(12):2261-2272. PubMed ID: 31444846
[TBL] [Abstract][Full Text] [Related]
11. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection.
El-Serag HB; Christie IC; Puenpatom A; Castillo D; Kanwal F; Kramer JR
Aliment Pharmacol Ther; 2019 Jun; 49(11):1442-1447. PubMed ID: 30932218
[TBL] [Abstract][Full Text] [Related]
12. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
14. Impact of direct acting antivirals (DAA) on neurologic disorders in chronic hepatitis C.
Chemello L; Cavalletto L; Ferrari S; Monaco S
Minerva Gastroenterol (Torino); 2021 Sep; 67(3):234-243. PubMed ID: 34672486
[TBL] [Abstract][Full Text] [Related]
15. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.
Dang H; Yeo YH; Yasuda S; Huang CF; Iio E; Landis C; Jun DW; Enomoto M; Ogawa E; Tsai PC; Le A; Liu M; Maeda M; Nguyen B; Ramrakhiani N; Henry L; Cheung R; Tamori A; Kumada T; Tanaka Y; Yu ML; Toyoda H; Nguyen MH
Hepatology; 2020 Jun; 71(6):1910-1922. PubMed ID: 31610027
[TBL] [Abstract][Full Text] [Related]
16. Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C.
Li J; Gordon SC; Zhou Y; Boscarino JA; Schmidt MA; Daida YG; Rupp LB; Trudeau S; Lu M;
Am J Gastroenterol; 2021 Mar; 116(3):576-583. PubMed ID: 33399360
[TBL] [Abstract][Full Text] [Related]
17. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
19. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
